Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Akero Therapeutics Inc shares valued at $1,619,340 were sold by Cheng Andrew on Oct 10 ’25. At $53.98 per share, Cheng Andrew sold 30,000 shares. The insider’s holdings dropped to 526,114 shares worth approximately $28.41 million following the completion of this transaction.
Also, Rolph Timothy sold 12,500 shares, netting a total of over 576,001 in proceeds. Following the sale of shares at $46.08 each, the insider now holds 166,571 shares.
Before that, Timothy Rolph had added 56,369 shares to its account. In a trade valued at $2,595,229, the Officer bought Akero Therapeutics Inc shares for $46.04 each.
Analysts at TD Cowen started covering the stock with ‘”a Buy”‘ outlook in a report released in early August. As of January 30, 2025, BofA Securities has increased its “Neutral” rating to a “Buy” for AKRO. Earlier on January 27, 2025, H.C. Wainwright resumed its rating. Their recommendation was “a Buy” for AKRO stock.
Analyzing AKRO Stock Performance
The stock’s lowest price that day was $53.84, but it reached a high of $54.07 in the same session. During the last five days, there has been a surge of approximately 0.73%. Over the course of the year, Akero Therapeutics Inc shares have jumped approximately 84.11%. Shares of the company reached a 52-week high of $58.40 on 01/27/25 and a 52-week low of $21.34 on 01/14/25.
Support And Resistance Levels for Akero Therapeutics Inc (AKRO)
According to the 24-hour chart, there is a support level at 53.87, which, if violated, would cause prices to drop to 53.74. In the upper region, resistance lies at 54.10. The next price resistance is at 54.20. RSI (Relative Strength Index) is 69.99 on the 14-day chart, showing neutral technical sentiment.
Is Akero Therapeutics Inc subject to short interest?
Stocks of Akero Therapeutics Inc saw a sharp steep in short interest on 2025-10-15 dropping by -3.28 million shares to 5.81 million. Data from Yahoo Finance shows that the short interest on 2025-09-15 was 9.09 million shares. A decline of -56.41% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 1.65 of the overall float, the days-to-cover ratio (short ratio) decline to 1.65.
Which companies own the most shares of Akero Therapeutics Inc (AKRO)?
Analysts anticipate Akero Therapeutics Inc stock to reach 56 by 2025, with the lowest price target being 54. In spite of this, 4 analysts ranked Akero Therapeutics Inc stock as Buy at the end of 2025. On November 18, 2024, Citigroup assigned a price target of “a Buy” to the stock and initiated coverage with a $65.
